TScan Therapeutics, Inc.
NASDAQ:TCRX · NASDAQ Global Market
-$0.01 today
Vol 0.81M · Avg 0.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-105.4%
avg -40.7%
ROIC
-62.5%
avg -44.6%
ROA
-56.7%
avg -37.6%
Analysis
ROA is currently the strongest return metric at -56.7% versus its period average of -37.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gavin MacBeath | Chief Executive Officer & Director | $818,650.00 | — | 56 | $1.17M | 1.91% |
Zoran Zdraveski | Chief Legal & Strategy Officer and Company Secretary | $657,200.00 | — | 56 | $350,000.00 | 0.57% |
Chrystal U. Louis | Chief Medical Officer | $618,200.00 | — | 50 | $420,000.00 | 0.69% |
Jason A. Amello | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | $606,800.00 | — | 58 | $350,000.00 | 0.57% |
Shrikanta Chattopadhyay | Senior Vice President & Head of Translational Medicine | — | — | — | — | — |
Stephen J. Elledge | Co-Founder & Chairman of Scientific Advisory Board | — | — | — | $0.00 | <0.01% |
Cagan Gurer | Senior Vice President of Discovery | — | — | — | — | — |
Jim Murray | Chief Development Operations Officer | — | — | — | — | — |
Stephen Camiolo | Senior Vice President of Market Access | — | — | — | $0.00 | <0.01% |
Tomasz Kula | Co-Founder & Member of Advisory Board | — | — | — | — | — |
Ann Hargraves | Chief Human Resources Officer | — | — | — | — | — |
Ray Lockard | Chief Manufacturing & Quality Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$145,525.97
Sells
0
$0.00
Net Sentiment
+$145,525.97
Net buying
Most Active
Lynx1 Capital Management LP
3 transactions
Analysis
Insiders reported 3 buys worth $145,525.97 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $145,525.97. Lynx1 Capital Management LP was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +168.7% | +22.4% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +168.7% over three years. Forward estimates point to Revenue at +22.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
Adicet Bio, Inc.
NASDAQ:ACET
$75.25M
XBiotech Inc.
NASDAQ:XBIT
$71.34M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Nutriband Inc.
NTRB
$41.21M
Lite Strategy, Inc.
LITS
$25.22M
Who manages TCRX?
TScan Therapeutics, Inc. (TCRX) lists 12 active executives. The top listed executive is Gavin MacBeath, Chief Executive Officer & Director.
Are TCRX insiders buying or selling?
Recent insider activity shows net buying of $58.18M.
Explore More
Continue the stock analysis
Jump to another research area for this company.